常规骨闪烁扫描在肝细胞癌患者分期中的效用有限:一项横断面研究。
Limited utility of routine bone scintigraphy in the staging of patients with hepatocellular carcinoma: a cross-sectional study.
发表日期:2024 Aug 13
作者:
Fatima Rodriguez-Alvarez, Blanca Zuleima Mota-Ayala, Ramiro Villavicencio-Martínez, Eric Kauffman-Ortega, Lucero Selene Téllez-Morán, Graciela Castro-Narro, Eleazar Ignacio-Alvarez, Jesús Alejandro Gabutti-Thomas, Carlos Moctezuma-Velazquez
来源:
Bone & Joint Journal
摘要:
最广泛使用的肝细胞癌 (HCC) 分期系统是巴塞罗那肝脏临床癌症 (BCLC) 系统,该系统考虑肿瘤负荷、体能状态和肝功能。肿瘤负荷通过腹部和胸部的横截面成像进行评估,围绕常规使用骨闪烁扫描(BS)检测肝外转移存在争议。本研究评估了 BS 在墨西哥患者 HCC 分期中的作用。对 2000 年至 2018 年墨西哥转诊中心所有患有 HCC 的成人进行回顾性横断面研究。分期包括腹部计算机断层扫描 (CT) 或磁共振成像、胸部 CT、和BS。主要结果是 BS 对分期和/或治疗计划的影响。在 238 名患者中,排除了 2 名纤维板层变异患者和 44 名数据不完整的患者。中位年龄为 66 岁,84% 患有肝硬化,主要病因是丙型肝炎病毒 (43%)。 BCLC 分期分布如下:A (14%)、B (7%)、C (68%) 和 D (11%)。 18% 存在肝外疾病;只有 8% 的患者 BS 呈阳性。阳性病例中,4例为真阳性,但没有改变分期或治疗计划。HCC分期中的常规BS表现出较低的阳性率,且假阳性率很高。考虑到肝外疾病的影响,对于传统标准之外的肝移植候选人来说,BS 可能是合理的。我们的研究强调了 BS 在早期 HCC 中的有限作用,并主张更有选择性地使用。版权所有 © 2024。由 Elsevier España, S.L.U. 出版。
The most widely used staging system for hepatocellular carcinoma (HCC) is the Barcelona Liver Clinic Cancer (BCLC) system, which considers tumor burden, performance status, and liver function. Tumor burden is assessed with cross sectional imaging of the abdomen and chest, controversy surrounds the routine use of bone scintigraphy (BS) for detecting extrahepatic metastases. This study evaluated the role of BS in staging HCC in Mexican patients.Retrospective cross-sectional study of all adults with HCC at a Mexican referral center from 2000 to 2018. Staging included abdominal computed tomography (CT) or magnetic resonance imaging, chest CT, and BS. The main outcome was the impact of BS on staging and/or therapy plans.Among 238 patients, 2 with fibrolamellar variant and 44 with incomplete data were excluded. Median age was 66 years, 84% had cirrhosis, and the predominant etiology was hepatitis C virus (43%). BCLC stages were distributed as follows: A (14%), B (7%), C (68%), and D (11%). Extrahepatic disease was present in 18%; only 8% patients had a positive BS. Among the positive cases, 4 were true positives, but they did not alter staging or therapy plans.Routine BS in HCC staging demonstrated low yield, with a notable rate of false positives. Considering the implications of extrahepatic disease, BS may be justified for liver transplant candidates outside conventional criteria. Our study highlights the limited role of BS in early-stage HCC and advocates for a more selective utilization.Copyright © 2024. Published by Elsevier España, S.L.U.